# Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors (Text with EEA relevance) EU Regulation No 273/2004 · adopted 11 February 2004 Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors (Text with EEA relevance) ## Introductory text Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors (Text with EEA relevance) THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof, Having regard to the proposal from the Commission, Having regard to the opinion of the European Economic and Social Committee, Acting in accordance with the procedure laid down in Article 251 of the Treaty, Whereas: (1) The United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, adopted in Vienna on 19 December 1988, hereinafter referred to as the ‘United Nations Convention’, was concluded by the Community by Council Decision 90/611/EEC. (2) The requirements of Article 12 of the United Nations Convention in respect of trade in drug precursors (i.e. substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances) have been implemented, as far as trade between the Community and third countries is concerned, by Council Regulation (EEC) No 3677/90 of 13 December 1990 laying down measures to be taken to discourage the diversion of certain substances to the illicit manufacture of narcotic drugs and psychotropic substances. (3) Article 12 of the United Nations Convention envisages adoption of appropriate measures to monitor the manufacture and distribution of precursors. This requires the adoption of measures relating to the trade in precursors among Member States. Such measures were introduced by Council Directive 92/109/EEC of 14 December 1992 on the manufacture and the placing on the market of certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances. To better ensure that harmonised rules are applied at the same time in all Member States, a regulation is considered to be more adequate than the current Directive. (4) In the context of the enlargement of the European Union, it is important to replace Directive 92/109/EEC by a regulation, as each modification of that Directive and its Annexes would trigger national implementation measures in 25 Member States. (5) By decisions taken at its 35th session in 1992, the United Nations Commission on Narcotic Drugs included additional substances in the tables of the Annex to the United Nations Convention. Corresponding provisions should be laid down in this Regulation in order to detect possible cases of illicit diversion of drug precursors in the Community and to ensure that common monitoring rules are applied in the Community market. (6) The provisions of Article 12 of the United Nations Convention are based on a system of monitoring trade in the substances in question. Most trade in these substances is entirely lawful. The documentation of consignments and labelling of these substances should be sufficiently explicit. It is furthermore important, whilst providing competent authorities with the necessary means of action, to develop, within the spirit of the United Nations Convention, mechanisms based on close cooperation with the operators concerned and on the development of intelligence gathering. (7) The measures applicable to sassafras oil are currently interpreted in different ways in the Community, since in some Member States it is regarded as a mixture containing Safrole and is therefore controlled, while other Member States regard it as a natural product not subject to controls. Inserting a reference to natural products in the definition of ‘scheduled substances’ will resolve this discrepancy and therefore allow controls to be applied to sassafras oil; only natural products from which scheduled substances can be extracted easily should be covered by the definition. (8) Substances commonly used in the illicit manufacture of narcotic drugs or psychotropic substances should be listed in an Annex. (9) It should be ensured that the manufacture or use of certain scheduled substances listed in Annex I is subject to possession of a licence. In addition, the supply of such substances should be permitted only where the persons to whom they are to be supplied are holders of a licence and have signed a customer declaration. The detailed rules concerning the customer declaration should be laid down in Annex III. (10) Measures should be adopted to encourage operators to notify the competent authorities of suspect transactions involving scheduled substances listed in Annex I. (11) Measures should be adopted in order to guarantee better control of intra-Community trade in scheduled substances listed in Annex I. (12) All transactions leading to the placing on the market of scheduled substances of categories 1 and 2 of Annex I should be properly documented. Operators should notify the competent authorities of any suspect transactions involving the substances listed in Annex I. However, exemptions should apply to transactions involving substances of category 2 of Annex I where the quantities involved do not exceed those indicated in Annex II. (13) A significant number of other substances, many of them traded legally in large quantities, have been identified as precursors to the illicit manufacture of synthetic drugs and psychotropic substances. To subject these substances to the same strict controls as those listed in Annex I would present an unnecessary obstacle to trade involving licences to operate and documentation of transactions. Therefore, a more flexible mechanism at Community level should be established whereby the competent authorities in the Member States are notified of such transactions. (14) The introduction of a cooperation procedure is provided for in the European Union action plan against drugs approved by the European Council of Santa Maria da Feira on 19 and 20 June 2000. In order to support cooperation between the competent authorities of the Member States and the chemicals industry, in particular with regard to substances which, although not referred to in this Regulation, might be used in the illicit manufacture of synthetic drugs and psychotropic substances, guidelines should be drawn up aimed at helping the chemical industry. (15) It is appropriate to make provision for the Member States to lay down rules on penalties applicable for infringement of the provisions of this Regulation. Given that the trade in drug precursors may lead to the illicit manufacture of synthetic drugs and psychotropic substances, Member States should be free to choose the most dissuasive penalties available under their national legislation. (16) The measures necessary for the implementation of this Regulation should be adopted in accordance with Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission. (17) Since the objectives of this Regulation, namely the harmonised monitoring of the trade in drug precursors and the avoidance of its diversion to the illicit manufacture of synthetic drugs and psychotropic substances, cannot be sufficiently achieved by the Member States and can therefore, by reason of the international and changeable nature of such trade, be better achieved at Community level, the Community may adopt measures, in accordance with the principle of subsidiarity as set out in Article 5 of the Treaty. In accordance with the principle of proportionality, as set out in that Article, this Regulation does not go beyond what is necessary in order to achieve those objectives. (18) Council Directive 92/109/EEC, Commission Directives 93/46/EEC, 2001/8/EC and 2003/101/EC and Commission Regulations (EC) No 1485/96 and (EC) No 1533/2000 should be repealed, HAVE ADOPTED THIS REGULATION: ## 1 Scope and objectives This Regulation establishes harmonised measures in Great Britain for the control and monitoring of certain substances frequently used for the illicit manufacture of narcotic drugs or psychotropic substances with a view to preventing the diversion of such substances. ## 2 Definitions For the purposes of this Regulation the following definitions shall apply: (a)‘scheduled substance’ means any substance listed in Annex I that can be used for the illicit manufacture of narcotic drugs or psychotropic substances, including mixtures and natural products containing such substances but excluding mixtures and natural products which contain scheduled substances and which are compounded in such a way that the scheduled substances cannot be easily used or extracted by readily applicable or economically viable means, medicinal products as defined in regulation 2 (medicinal products) of the Human Medicines Regulations 2012 and veterinary medicinal products as defined in regulation 2 of the Veterinary Medicines Regulations 2013 ; (b)‘non-scheduled substance’ means any substance which, although not listed in Annex I, is identified as having been used for the illicit manufacture of narcotic drugs or psychotropic substances; (c)‘placing on the market’ means any supply, whether in return for payment or free of charge, of scheduled substances in Great Britain; or the storage, manufacture, production, processing, trade, distribution or brokering of these substances for the purpose of supply in Great Britain; (d)‘operator’ means any natural or legal person engaged in the placing on the market of scheduled substances; (e)‘International Narcotics Control Board’ means the Board established by the Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol; (f)‘special licence’ means a licence that is granted to a particular type of operator; (g)‘special registration’ means a registration that is made for a particular type of operator; (h)‘user’ means a natural or legal person other than an operator who possesses a scheduled substance and is engaged in the processing, formulation, consumption, storage, keeping, treatment, filling into containers, transfer from one container to another, mixing, transformation or any other utilisation of scheduled substances; (i)‘natural product’ means— (i)an organism or a part thereof, in any form; or (ii)a naturally occurring substance which is unprocessed or processed only by manual, mechanical or gravitational means, by dissolution in water, by flotation, by extraction with water, by steam distillation or by heating solely to remove water, or which is extracted from air by any means. ## 3 Requirements for the placing on the market of scheduled substances 1. Operators wishing to place on the market scheduled substances of categories 1 and 2 of Annex I shall be required to appoint an officer responsible for the trade in scheduled substances, to notify the competent authorities of the name and contact details of that officer and to notify them immediately of any subsequent modification of this information. The officer shall ensure that the trade in scheduled substances conducted by the operator takes place in compliance with this Regulation. The officer shall be empowered to represent the operator and to take the decisions necessary for performing the tasks specified above. 2. Operators and users shall obtain a licence from the competent authorities ... before they may possess or place on the market scheduled substances of category 1 of Annex I. The competent authorities may grant special licences to pharmacies, dispensaries of veterinary medicine, certain types of public authorities or armed forces. Such special licences shall be valid only for the use of scheduled substances of category 1 of Annex I within the scope of the official duties of the operators concerned. 3. Any operator holding a licence shall supply scheduled substances of category 1 of Annex I only to operators or users who also hold a licence and have signed a customer declaration as provided for in Article 4(1). 4. When considering whether to grant a licence, the competent authorities shall take into account in particular the competence and integrity of the applicant. The licence is to be refused if there are reasonable grounds for doubting the suitability and reliability of the applicant or of the officer responsible for the trade in scheduled substances. The licence may be suspended or revoked by the competent authorities whenever there are reasonable grounds for believing that the holder is no longer a fit and proper person to hold a licence, or that the conditions under which the licence was granted are no longer fulfilled. 5. Without prejudice to paragraph 8, the competent authorities may either limit the validity of the licence to a period not exceeding three years or may oblige the operators and users to demonstrate at intervals not exceeding three years that the conditions under which the licence was granted are still fulfilled. The licence shall mention the operation or operations for which it is valid, as well as the scheduled substances concerned. The competent authorities shall, in principle, grant special licences for an unlimited duration but may suspend or revoke them where there are reasonable grounds for believing that the holder is no longer a fit and proper person to hold a licence, or that the conditions under which the licence was granted are no longer fulfilled. 6. Operators shall obtain registration from the competent authorities ... before placing on the market scheduled substances of category 2 of Annex I. From 1 July 2015 users shall obtain a registration from the competent authorities ... before possessing scheduled substances of subcategory 2A of Annex I. The competent authorities may grant special registrations to pharmacies, dispensaries of veterinary medicine, certain types of public authorities or the armed forces. Such special registrations shall be considered valid only for the use of scheduled substances of category 2 of Annex I within the scope of the official duties of the operators or users concerned. 6a. Any operator holding a registration shall supply scheduled substances of subcategory 2A of Annex I only to other operators or users who also hold a registration and have signed a customer declaration as provided for in Article 4(1). 6b. When considering whether to grant registration, the competent authorities shall take into account, in particular, the competence and integrity of the applicant. They shall refuse registration if there are reasonable grounds for doubting the suitability and reliability of the applicant or of the officer responsible for the trade in scheduled substances. They may suspend or revoke registration where there are reasonable grounds for believing that the holder is no longer a fit and proper person to hold a registration, or that the conditions under which registration was granted are no longer fulfilled. 6c. The competent authorities may require operators and users to pay a fee for the application for a licence or for registration. Where a fee is levied, competent authorities shall consider adjusting the level of the fee depending on the size of the enterprise. Such a fee shall be levied in a non-discriminatory manner and shall not exceed the cost of processing the application. 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8. The Secretary of State may prescribe by regulations the requirements and conditions (including, in the case of a licence or registration, the payment of a prescribed fee) for: (a) granting the licence, including, where relevant, the categories of personal data to be provided; (b) granting registration, including where relevant the categories of personal data to be provided; (c) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... ## 4 Customer declaration 1. Without prejudice to paragraph 4 of this Article, and to Articles 6 and 14, any operator established within Great Britain who supplies a customer with a scheduled substance of category 1 or 2 of Annex I shall obtain a declaration from the customer which shows the specific use or uses of the scheduled substances. The operator shall obtain a separate declaration for each scheduled substance. That declaration shall conform to the model set out in point 1 of Annex III. In the case of legal persons, the declaration shall be made on headed notepaper. 2. As an alternative to the above declaration for an individual transaction, an operator who regularly supplies a customer with a scheduled substance of category 2 of Annex I may accept a single declaration in respect of a number of transactions involving this scheduled substance over a period not exceeding one year, provided that the operator is satisfied that the following criteria have been met: (a) the customer has been supplied by the operator with the substance on at least three occasions in the preceding 12 months; (b) the operator has no reason to suppose that the substance will be used for illicit purposes; (c) the quantities ordered are consistent with the usual consumption for that customer. This declaration shall conform to the model set out in point 2 of Annex III. In the case of legal persons, the declaration shall be made on headed notepaper. 3. An operator supplying scheduled substances of category 1 of Annex I shall stamp and date a copy of the declaration, certifying it to be a true copy of the original. Such copy shall always accompany those substances being moved within Great Britain and shall be presented on request to the authorities responsible for checking vehicle contents during transport operations. 4. The Secretary of State may prescribe by regulations requirements and conditions for obtaining and using customer declarations. ## 5 Documentation 1. Without prejudice to Article 6, operators shall ensure that all transactions leading to the placing on the market of scheduled substances of categories 1 and 2 of Annex I are properly documented in accordance with paragraphs 2 to 5 below. This obligation shall not apply to those operators who hold special licences or are subject to special registration pursuant to Article 3(2) and (6) respectively. 2. Commercial documents such as invoices, cargo manifests, administrative documents, transport and other shipping documents shall contain sufficient information to identify positively: (a) the name of the scheduled substance as given in categories 1 and 2 of Annex I; (b) the quantity and weight of the scheduled substance and, where a mixture or natural product is concerned, the quantity and weight, if available, of the mixture or natural product as well as the quantity and weight, or the percentage by weight, of any substance or substances of categories 1 and 2 of Annex I which are contained in the mixture; (c) the name and address of the supplier, distributor, consignee, and, if possible, of other operators directly involved in the transaction, as referred to in Article 2(c) and (d). 3. The documentation must also contain a customer declaration as referred to in Article 4. 4. Operators shall keep such detailed records of their activities as are required to comply with their obligations under paragraph 1. 5. The documentation and records referred to in paragraphs 1 to 4 shall be kept for at least three years from the end of the calendar year in which the transaction referred to in paragraph 1 took place, and must be readily available for inspection by the competent authorities upon request. 6. The documentation may also be kept in the form of reproductions on an image medium or other data media. It must be ensured that the data stored: (a) match the documentation in appearance and content when made readable, and (b) are readily available at all times, can be made readable without delay and can be analysed by automated means for the duration of the period specified in paragraph 5. 7. The Secretary of State may prescribe by regulations requirements and conditions for the documentation of mixtures containing scheduled substances. ## 6 Exemptions The obligations according to Articles 3, 4 and 5 shall not apply to transactions involving scheduled substances of category 2 of Annex I where the quantities involved do not exceed those indicated in Annex II over a period of one year. ## 7 Labelling Operators shall ensure that labels are affixed to scheduled substances of categories 1 and 2 of Annex I before they are supplied. The labels must show the names of the substances as given in Annex I. Operators may in addition affix their customary labels. The Secretary of State may prescribe by regulations requirements and conditions for the labelling of mixtures containing scheduled substances. ## 8 Notification of the competent authorities 1. Operators shall notify the competent authorities immediately of any circumstances, such as unusual orders or transactions involving scheduled substances to be placed on the market, which suggest that such substances might be diverted for the illicit manufacture of narcotic drugs or psychotropic substances. To that end, operators shall provide any available information allowing the competent authorities to verify the legitimacy of the relevant order or transaction. 2. Operators shall provide the competent authorities with relevant information in summary form about their transactions involving scheduled substances. 3. The Secretary of State may prescribe by regulations the requirements and conditions for operators to provide information as referred to in paragraph 2 of this Article including, where relevant, the categories of personal data to be processed for that purpose and the safeguards for processing such personal data. 4. Operators shall not disclose any personal data collected pursuant to this Regulation other than to the competent authorities. ## 9 Guidelines 1. The Secretary of State must draw up, and keep up to date, guidelines to facilitate cooperation between the competent authorities, the operators, and the chemical industry, in particular as regards non-scheduled substances. 2. The guidelines shall provide in particular: (a) information on how to recognise and notify suspect transactions; (b) a regularly updated list of non-scheduled substances to enable the industry to monitor on a voluntary basis the trade in such substances; (c) other information which may be deemed useful. 3. The competent authorities shall ensure that the guidelines and the list of non-scheduled substances are regularly disseminated in a manner deemed appropriate by the competent authorities in accordance with the objectives of the guidelines. ## 10 Powers and obligations of competent authorities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ## 11 Cooperation between the Member States and the Commission . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ## 12 Penalties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ## 13 Report to International Narcotics Control Board 1. To permit the necessary adjustments to the arrangements for monitoring trade in scheduled substances and non-scheduled substances, the Secretary of State must draw up a report annually summarising all relevant information on the implementation of the monitoring measures laid down in this Regulation, in particular as regards the substances used for the illicit manufacture of narcotic drugs or psychotropic substances and methods of diversion and illicit manufacture, and their licit trade. 2. The report mentioned in paragraph 1 must be submitted by the Secretary of State to the International Narcotics Control Board in accordance with article 12(12) of the United Nationals Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, adopted in Vienna on 19 December 1988. ## 13a European database on drug precursors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ## 13b Data protection 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2. Without prejudice to the Data Protection Act 2018, personal data obtained or processed pursuant to this Regulation shall be used solely for the purpose of preventing the diversion of scheduled substances. 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ## 14 Implementing acts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ## 14a Committee procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ## 15 Adaptation of Annexes The Secretary of State may make regulations to amend Annexes I, II and III to adapt to new trends in diversion of drug precursors and to follow any amendment to the tables in the Annex to the United Nations Convention. ## 15a Regulations 1. A power of the Secretary of State to make regulations under this Regulation is to be exercised by statutory instrument which may not be made unless a draft of the instrument has been laid before, and approved by a resolution of, each House of Parliament. 2. Regulations may make different provision for different purposes and may include such incidental, supplemental, consequential, transitional, transitory or saving provision as the Secretary of State considers appropriate. ## 16 Information about measures adopted by Member States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ## 17 Repeals 1. Council Directive 92/109/EEC, Commission Directives 93/46/EEC, 2001/8/EC and 2003/101/EC and Commission Regulations (EC) No 1485/96 and (EC) No 1533/2000 are hereby repealed. 2. References to the repealed directives or regulations shall be construed as being made to this Regulation. 3. The validity of any register established, any licences granted and any customer declarations issued under the repealed directives or regulations shall not be affected. ## 18 Entry into force This Regulation shall enter into force on 18 August 2005, except for Articles 9, 14 and 15, which shall enter into force on the day of publication of this Regulation in the Official Journal of the European Union, in order to permit the adoption of the measures provided for in those Articles. Such measures shall enter into force at the earliest on 18 August 2005. ## Signature ... ## Annex I List of scheduled substances CATEGORY 1 Substance CN designation (if different) CN code CAS No (1)OJ No. L 290, 28.10.2002, p. 1. (2)The CAS No is the ‘chemical abstracts service registry number’, which is a unique numeric identifier specific to each substance and its structure. The CAS No is specific to each isomer and to each salt of each isomer. The CAS Nos for the salts of the substances listed above will be different to those given. (3)Also named (+)-norpseudoephedrine, CN code 2939 43 00, CAS No 492-39-7. (4)Also known as ethyl 3-oxo-2-phenylbutanoate, according to The International Union of Pure and Applied Chemistry (IUPAC (5)Also known as methyl 2-(2H-1,3-benzodioxol-5-yl)-3-oxobutanoate, according to IUPAC. (6)And its ethyl, methyl (CAS No 80532-66-7), propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl esters, with the same CN code as BMK glycidic acid. (7)And its ethyl (CAS No 28578-16-7), methyl (CAS No 13605-48-6), propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl esters, with the same CN code as PMK glycidic acid. (8)Also known as 5-[2-(1,3-benzodioxol-5-yl)acetyl]–2,2-dimethyl–1,3-dioxane–4,6-dione, according to IUPAC. 1-phenyl-2-propanone Phenylacetone 2914 31 00 103-79-7 Diethyl (phenylacetyl) propanedioate (also referred to as DEPAPD) 2918 30 00 20320-59-6 Methyl alpha-phenylacetoacetate (also referred to as MAPA) 2918 30 00 16648-44-5 Ethyl alpha-phenylacetoacetate (also referred to as EAPA) Ex 2918 30 00 5413-05-8 2-methyl-3-phenyloxirane-2-carboxylic acid (also referred to as BMK glycidic acid) 2918 99 90 25547-51-7 N-acetylanthranilic acid 2-Acetamidobenzoic acid 2924 23 00 89-52-1 Alpha-phenylacetoacetamide (also referred to as APAA) 2924 29 70 4433-77-6 Alpha-phenylacetoacetonitrile (also referred to as APAAN) 2926 40 00 4468-48-8 Isosafrol (cis + trans) 2932 91 00 120-58-1 3,4-methylenedioxyphenylpropan-2-one 1-(1,3-Benzodioxol-5-yl)propan-2-one 2932 92 00 4676-39-5 Piperonal 2932 93 00 120-57-0 Safrole 2932 94 00 94-59-7 Methyl 3-oxo-2-(3,4-methylenedioxyphenyl)butanoate (also referred to as MAMDPA) Methyl 3-oxo-2-(3,4-methylenedioxyphenyl)butanoate Ex 2932 99 00 1369021-80-6 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (also referred to as PMK glycidic acid) 2932 99 00 2167189-50-4 Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (also referred to as IMDPAM) IMDPAM 2932 99 00 N-phenyl-1-(2-phenylethyl)piperidin-4-amine 4-anilino-N-phenethylpiperidine (ANPP) 2933 36 00 21409-26-7 1-(2-phenylethyl)piperidin-4-one N-phenethyl-4-piperidone (NPP) 2933 37 00 39742-60-4 N-phenylpiperidin-4-amine (also referred to as 4-AP) 2933 39 99 23056-29-3 Tert-butyl 4-anilinopiperidine-1-carboxylate (also referred to as 1-boc-4-AP) 2933 39 99 125541-22-2 N-phenyl-N-(piperidin-4-yl)propanamide (also referred to as norfentanyl) 2933 39 99 1609-66-1 4-piperidone Piperidin-4-one 2933 39 99 41661-47-6 1-boc-4-piperidone tert-butyl 4-oxopiperidine-1-carboxylate 2933 39 99 79099-07-3 Ephedrine 2939 41 00 299-42-3 Pseudoephedrine 2939 42 00 90-82-4 Norephedrine 2939 44 00 14838-15-4 Ergometrine 2939 61 00 60-79-7 Ergotamine 2939 62 00 113-15-5 Lysergic acid 2939 63 00 82-58-6 The stereoisomeric forms of the substances listed in this category not being cathine , whenever the existence of such forms is possible. The salts of the substances listed in this category, whenever the existence of such salts is possible and not being the salts of cathine. (1R,2S)-(-)-chloroephedrine 2939 79 90 110925-64-9 (1S,2R)-(+)-chloroephedrine 2939 79 90 1384199-95-4 (1S,2S)-(+)-chloropseudoephedrine 2939 79 90 73393-61-0 (1R,2R)-(-)-chloropseudoephedrine 2939 79 90 771434-80-1 CATEGORY 2 Substance CN designation (if different) CN code CAS No Red phosphorus 2804 70 10 7723-14-0 Acetic anhydride 2915 24 00 108-24-7 The salts of the substances listed in this category, whenever the existence of such salts is possible. SUBCATEGORY 2B OJ L 290, 28.10.2002, p. 1 . The CAS No is the ‘ chemical abstracts service registry number ’ , which is a unique numeric identifier specific to each substance and its structure. The CAS No is specific to each isomer and to each salt of each isomer. It must be understood that the CAS Nos for the salts of the substances listed above will be different to those given. Substance CN designation (if different) CN code CAS No Phenylacetic acid 2916 34 00 103-82-2 Anthranilic acid ex 2922 43 00 118-92-3 Piperidine 2933 32 00 110-89-4 Potassium permanganate 2841 61 00 7722-64-7 The salts of the substances listed in this category, whenever the existence of such salts is possible. CATEGORY 3 OJ L 290, 28.10.2002, p. 1. The CAS No is the ‘chemical abstracts service registry number’, which is a unique numeric identifier specific to each substance and its structure. The CAS No is specific to each isomer and to each salt of each isomer. It must be understood that the CAS Nos for the salts of the substances listed above will be different to those given. Substance CN designation(if different) CN code CAS No Hydrochloric acid Hydrogen chloride 2806 10 00 7647-01-0 Sulphuric acid 2807 00 00 7664-93-9 Toluene 2902 30 00 108-88-3 Ethyl ether Diethyl ether 2909 11 00 60-29-7 Acetone 2914 11 00 67-64-1 Methylethylketone Butanone 2914 12 00 78-93-3 The salts of the substances listed in this category, whenever the existence of such salts is possible and not being the salts of hydrochloric acid and sulphuric acid. ## Annex II Substance Threshold Acetic anhydride 100 L Potassium permanganate 100 kg Anthranilic acid and its salts 1 kg Phenylacetic acid and its salts 1 kg Piperidine and its salts 0.5 kg Red phosphorus 0.1kg ## 1 Model declaration relating to individual transactions (category 1 or 2) ## 2 Model declaration relating to multiple transactions (category 2) --- Source: https://www.legislation.gov.uk/eur/2004/273 (the official version) Page: https://openlegislation.uk/eu-regulation-2004-273 Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.